生化反应低于0.1 ng/ml可预测前列腺癌患者接受前列腺特异性膜抗原靶向挽救性手术后的无治疗生存期
这项队列研究在三个三级中心纳入2014至2022年间根治性前列腺切除术后生化复发、PSMA PET显示寡复发并接受PSMA放射引导挽救性手术的患者,评估术后PSA反应与无治疗生存期(TFS)的关系。结果显示术后PSA<0.1 ng/ml者2年TFS率为81.1%,高于0.1-<0.2 ng/ml者的56.1%和>0.2 ng/ml者的43.1%(p<0.001),多因素分析中PSA 0.1-0.2 ng/ml(HR 1.9)和≥0.2 ng/ml(HR 3.2)独立预测需额外治疗。作者认为较低的生化反应似乎可预测更长的TFS。
要点
- 术后PSA<0.1 ng/ml者2年TFS率为81.1%,高于0.1-<0.2 ng/ml者的56.1%和>0.2 ng/ml者的43.1%(p<0.001)。
- 作者认为术后PSA<0.1 ng/ml似乎可预测更长的无治疗生存期,可能有助于术后咨询和及时选择额外治疗。
核心结论
- 对于接受挽救性PSMA放射引导手术后的患者,较低的生化反应(PSA<0.1 ng/ml)似乎可预测更长的无治疗生存期。
- 这一认识可能有助于术后对患者进行咨询以及指导及时选择额外治疗。
研究设计与样本
- 这项队列研究评估了根治性前列腺切除术后生化复发且PSMA PET显示寡复发前列腺癌、并在三个三级中心接受PSMA放射引导挽救性手术的患者(2014-2022年)。
- 共评估553例患者,其中522例(94%)在PSMA放射引导挽救性手术中切除了转移性软组织病灶。
主要发现
- PSMA放射引导挽救性手术后2-16周,分别有192例、62例和190例患者达到PSA<0.1、0.1-<0.2和>0.2 ng/ml。
- 随访2年时,PSA<0.1、0.1-<0.2和>0.2 ng/ml患者的无治疗生存率分别为81.1%、56.1%和43.1%(p<0.001)。
关键数值与推荐
- 术后PSA反应分为<0.1、0.1-<0.2和>0.2 ng/ml三组。
临床怎么用
- 作者认为术后PSA<0.1 ng/ml似乎可预测更长的无治疗生存期,可能有助于术后咨询和及时选择额外治疗。
局限性
- 主要局限性是缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a subset of patients with oligorecurrent prostate cancer (PCa), salvage surgery with prostate-specific membrane antigen (PSMA) radioguided surgery (PSMA-RGS) seems to be of value. OBJECTIVE: To evaluate whether a lower level of postoperative prostate-specific antigen (PSA; <0.1 ng/ml) is predictive of therapy-free survival (TFS) following salvage PSMA-RGS. DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated patients with biochemical recurrence after radical prostatectomy and oligorecurrent PCa on PSMA positron emission tomography treated with PSMA-RGS in three tertiary care centers (2014-2022). INTERVENTION: PSMA-RGS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Postsalvage surgery PSA response was categorized as <0.1, 0.1-<0.2, or >0.2 ng/ml. Kaplan-Meier and multivariable Cox regression models evaluated TFS according to PSA response. RESULTS AND LIMITATIONS: Among 553 patients assessed, 522 (94%) had metastatic soft tissue lesions removed during PSMA-RGS. At 2-16 wk after PSMA-RGS, 192, 62, and 190 patients achieved PSA levels of <0.1, 0.1-<0.2, and >0.2 ng/ml, respectively. At 2 yr of follow-up, TFS rate was 81.1% versus 56.1% versus 43.1% (p < 0.001) for patients with PSA <0.1 versus 0.1-<0.2 versus >0.2 ng/ml. In multivariable analyses, PSA levels of 0.1-0.2 ng/ml (hazard ratio [HR]: 1.9, confidence interval [CI]: 1.1-3.1) and ≥0.2 ng/ml (HR: 3.2, CI: 2.2-4.6, p < 0.001) independently predicted the need for additional therapy after PSMA-RGS. The main limitation is the lack of a control group. CONCLUSIONS: For patients after salvage PSMA-RGS, a lower biochemical response (PSA <0.1 ng/ml) seems to predict longer TFS. This insight may help in counseling patients postoperatively as well as guiding the timely selection of additional therapy. PATIENT SUMMARY: We studied what happened to prostate cancer patients in three European centers who had salvage surgery using a special method called prostate-specific membrane antigen-targeted radioguidance. We found that patients who had low prostate-specific antigen levels soon after surgery were less likely to need further treatment for a longer time.
引用
- Knipper S, Lischewski F, Koehler D, et al. Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery. Eur Urol Oncol. 2024. PMID: 38729805. doi:10.1016/j.euo.2024.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。